Stanley T Crooke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4435539/publications.pdf

Version: 2024-02-01

211 papers	14,636 citations	17405 63 h-index	21474 114 g-index
214 all docs	214 docs citations	214 times ranked	10495 citing authors

#	Article	IF	Citations
1	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 375, 998-1006.	6.3	813
2	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, The, 2016, 388, 2239-2253.	6.3	584
3	RNA-Targeted Therapeutics. Cell Metabolism, 2018, 27, 714-739.	7.2	556
4	Mitomycin C: a review. Cancer Treatment Reviews, 1976, 3, 121-139.	3.4	430
5	Cellular uptake and trafficking of antisense oligonucleotides. Nature Biotechnology, 2017, 35, 230-237.	9.4	416
6	Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. Journal of Biological Chemistry, 2003, 278, 7108-7118.	1.6	403
7	Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans. Circulation Research, 2013, 112, 1479-1490.	2.0	326
8	Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery, 2021, 20, 427-453.	21.5	299
9	Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature, 1988, 334, 268-270.	13.7	266
10	Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. Journal of Lipid Research, 2007, 48, 763-767.	2.0	266
11	Molecular Mechanisms of Antisense Oligonucleotides. Nucleic Acid Therapeutics, 2017, 27, 70-77.	2.0	255
12	Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs. Journal of Biological Chemistry, 2004, 279, 17181-17189.	1.6	250
13	Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression. Cell, 2012, 150, 895-908.	13.5	250
14	Single-Stranded siRNAs Activate RNAi in Animals. Cell, 2012, 150, 883-894.	13.5	239
15	Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. Journal of Medicinal Chemistry, 1986, 29, 218-223.	2.9	222
16	Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nature Biotechnology, 2019, 37, 640-650.	9.4	205
17	RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Molecular Therapy, 2017, 25, 2075-2092.	3.7	168
18	Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8012-8017.	3.3	165

#	Article	IF	Citations
19	Human RNase III Is a 160-kDa Protein Involved in Preribosomal RNA Processing. Journal of Biological Chemistry, 2000, 275, 36957-36965.	1.6	164
20	Phosphorothioate modified oligonucleotideâ€“protein interactions. Nucleic Acids Research, 2020, 48, 5235-5253.	6.5	163
21	Antisense Strategies. Current Molecular Medicine, 2004, 4, 465-487.	0.6	157
22	Etoposide (VP-16-213). Cancer Treatment Reviews, 1979, 6, 107-124.	3.4	155
23	Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. Journal of Medicinal Chemistry, 1987, 30, 2181-2190.	2.9	155
24	Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Research, 2015, 43, 2927-2945.	6.5	151
25	Antisense technology: A review. Journal of Biological Chemistry, 2021, 296, 100416.	1.6	149
26	Properties of Cloned and Expressed Human RNase H1. Journal of Biological Chemistry, 1999, 274, 28270-28278.	1.6	148
27	Maytansine. Cancer Treatment Reviews, 1978, 5, 199-207.	3.4	145
28	Clinical pharmacological properties of mipomersen (<scp>K</scp>ynamro), a second generation antisense inhibitor of apolipoprotein <scp>B</scp>. British Journal of Clinical Pharmacology, 2013, 76, 269-276.	1.1	145
29	Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Research, 2016, 44, 2093-2109.	6.5	142
30	Progress in antisense technology: The end of the beginning. Methods in Enzymology, 2000, 313, 3-45.	0.4	141
31	Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (KynamroÂ®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B. Clinical Pharmacokinetics, 2015, 54, 133-146.	1.6	138
32	Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nature Biotechnology, 2016, 34, 875-880.	9.4	137
33	Binding Affinity and Specificity of Escherichia coli RNase H1:â€‰ Impact on the Kinetics of Catalysis of Antisense Oligonucleotideâ€“RNA Hybrids. Biochemistry, 1997, 36, 390-398.	1.2	127
34	Progress toward oligonucleotide therapeutics: pharmacodynamic properties. FASEB Journal, 1993, 7, 533-539.	0.2	118
35	An Overview of Progress in Antisense Therapeutics. Oligonucleotides, 1998, 8, 115-122.	4.4	106
36	Binding and Cleavage Specificities of Human Argonaute2. Journal of Biological Chemistry, 2009, 284, 26017-26028.	1.6	104

#	Article	IF	Citations
37	Peptidoleukotrienes: Distinct receptors for leukotriene C4 and D4 in the Guinea-pig lung. Biochemical and Biophysical Research Communications, 1983, 116, 1136-1143.	1.0	103
38	The Effects of 2â€²-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials. Nucleic Acid Therapeutics, 2017, 27, 121-129.	2.0	101
39	2â€²-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF. Nucleic Acids Research, 2015, 43, 4569-4578.	6.5	97
40	Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochemical Pharmacology, 1986, 35, 923-932.	2.0	95
41	Rapid Identification of Emerging Pathogens: Coronavirus. Emerging Infectious Diseases, 2005, 11, 373-379.	2.0	94
42	Molecular Mechanisms of Antisense Drugs: RNase H. Oligonucleotides, 1998, 8, 133-134.	4.4	92
43	The signal transduction system of the leukotriene D4 receptor. Trends in Pharmacological Sciences, 1989, 10, 103-107.	4.0	91
44	Integrated Safety Assessment of 2â€²-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers. Molecular Therapy, 2016, 24, 1771-1782.	3.7	91
45	Phosphorothioate oligonucleotides can displaceNEAT1RNA and form nuclear paraspeckle-like structures. Nucleic Acids Research, 2014, 42, 8648-8662.	6.5	87
46	Integrated Assessment of the Clinical Performance of GalNAc₃-Conjugated 2â€²-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience. Nucleic Acid Therapeutics, 2019, 29, 16-32.	2.0	85
47	Vitraveneâ„¢â€”Another Piece in the Mosaic. Oligonucleotides, 1998, 8, vii-viii.	4.4	84
48	ViableRNaseH1knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function. Nucleic Acids Research, 2016, 44, 5299-5312.	6.5	84
49	Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Research, 2007, 35, 6598-6610.	6.5	83
50	Antisense oligonucleotides targeting translation inhibitory elements in 5â€² UTRs can selectively increase protein levels. Nucleic Acids Research, 2017, 45, 9528-9546.	6.5	83
51	Human RNase H1 Discriminates between Subtle Variations in the Structure of the Heteroduplex Substrate. Molecular Pharmacology, 2007, 71, 83-91.	1.0	82
52	Cloning and expression of a yeast copper metallothionein gene. Gene, 1984, 27, 23-33.	1.0	81
53	TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. Nucleic Acids Research, 2014, 42, 7819-7832.	6.5	80
54	Multiplexed Screening of Neutral Mass-Tagged RNA Targets against Ligand Libraries with Electrospray Ionization FTICR MS:Â A Paradigm for High-Throughput Affinity Screening. Analytical Chemistry, 1999, 71, 3436-3440.	3.2	78

#	Article	IF	Citations
55	Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Research, 2019, 47, 5465-5479.	6.5	77
56	The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with Proteins Is a Critical Determinant of the Therapeutic Effects of These Agents. Journal of the American Chemical Society, 2020, 142, 14754-14771.	6.6	77
57	Role of intravesical mitomycin c in management of superficial bladder tumors. Urology, 1980, 16, 11-15.	0.5	76
58	A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clinical Pharmacology and Therapeutics, 1994, 56, 641-646.	2.3	75
59	Potential roles of antisense technology in cancer chemotherapy. Oncogene, 2000, 19, 6651-6659.	2.6	74
60	Investigating the Structure of Human RNase H1 by Site-directed Mutagenesis. Journal of Biological Chemistry, 2001, 276, 23547-23553.	1.6	74
61	Structural Requirements at the Catalytic Site of the Heteroduplex Substrate for Human RNase H1 Catalysis. Journal of Biological Chemistry, 2004, 279, 36317-36326.	1.6	72
62	Acute hepatotoxicity of 2â€² fluoro-modified 5â€“10â€“5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Nucleic Acids Research, 2018, 46, 2204-2217.	6.5	71
63	Identification of metabolically stable 5â€²-phosphate analogs that support single-stranded siRNA activity. Nucleic Acids Research, 2015, 43, 2993-3011.	6.5	67
64	Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2â€²-modifications and enhances antisense activity. Nucleic Acids Research, 2016, 44, 3892-3907.	6.5	65
65	Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer, 1977, 39, 1430-1434.	2.0	63
66	Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Research, 2020, 48, 1691-1700.	6.5	63
67	Interactions of gold coordination complexes with DNA. Biochemical Pharmacology, 1986, 35, 1427-1433.	2.0	62
68	Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line. Life Sciences, 1986, 39, 37-45.	2.0	62
69	Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice. Nucleic Acids Research, 2011, 39, e13-e13.	6.5	62
70	Effect of leukotrienes, bradykinin and calcium ionophore (A 23187) on bovine endothelial cells: Release of prostacyclin. Prostaglandins, 1986, 31, 157-166.	1.2	61
71	Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. Nucleic Acids Research, 2021, 49, 9026-9041.	6.5	61
72	Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Research, 2017, 45, 5309-5322.	6.5	60

#	Article	IF	Citations
73	The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. Nucleic Acids Research, 2015, 43, 8955-8963.	6.5	59
74	Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides. Nucleic Acids Research, 2016, 44, gkw595.	6.5	58
75	Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Research, 2018, 46, 3579-3594.	6.5	58
76	Molecular mechanisms of action of auranofin and other gold complexes as related to their biologic activities. American Journal of Medicine, 1983, 75, 109-113.	0.6	57
77	Cleavage of Single Strand RNA Adjacent to RNA-DNA Duplex Regions by Escherichia coli RNase H1. Journal of Biological Chemistry, 1997, 272, 27513-27516.	1.6	57
78	Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions. PLoS ONE, 2016, 11, e0161930.	1.1	57
79	RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery. Nucleic Acids Research, 2016, 44, 3351-3363.	6.5	57
80	Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms. PLoS ONE, 2014, 9, e108625.	1.1	56
81	Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins. Journal of the American Chemical Society, 2020, 142, 7456-7468.	6.6	56
82	Identification and characterization of leukotriene D4 receptors in adult and fetal human lung. Biochemical Pharmacology, 1985, 34, 4311-4317.	2.0	55
83	The Effects of 2â€²-O-Methoxyethyl Oligonucleotides on Renal Function in Humans. Nucleic Acid Therapeutics, 2018, 28, 10-22.	2.0	55
84	Antisense drug discovery and development technology considered in a pharmacological context. Biochemical Pharmacology, 2021, 189, 114196.	2.0	55
85	Molecular Cloning and Expression of cDNA for Human RNase H. Oligonucleotides, 1998, 8, 53-61.	4.4	54
86	Differential effects of manoalide on secreted and intracellular phospholipases. Biochemical Pharmacology, 1987, 36, 733-740.	2.0	53
87	Thiol competition for Et3PAuS-albumin: a nonenzymatic mechanism for Et3PO formation. Journal of Inorganic Biochemistry, 1987, 30, 177-187.	1.5	52
88	The cellular pharmacology of auranofin. Seminars in Arthritis and Rheumatism, 1987, 17, 71-80.	1.6	51
89	Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides. Advances in Pharmacology, 1997, 40, 1-49.	1.2	51
90	Identification and Partial Purification of Human Double Strand RNase Activity. Journal of Biological Chemistry, 1998, 273, 2532-2542.	1.6	50

#	Article	IF	Citations
91	Depletion of key protein components of the RISC pathway impairs pre-ribosomal RNA processing. Nucleic Acids Research, 2011, 39, 4875-4889.	6.5	50
92	Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides. Nucleic Acids Research, 2017, 45, 10649-10671.	6.5	50
93	Antisense Therapeutics. Biotechnology and Genetic Engineering Reviews, 1998, 15, 121-158.	2.4	48
94	Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells. Nucleic Acid Therapeutics, 2019, 29, 245-255.	2.0	48
95	Low-Molecular-Weight Nuclear RNAs. Perspectives in Biology and Medicine, 1971, 15, 117-139.	0.3	47
96	The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli RNase H1 Activity. Journal of Biological Chemistry, 1997, 272, 18191-18199.	1.6	47
97	Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration212Abbreviations: HSV, herpes simplex virus; CGE, capillary gel electrophoresis; and HPLC/ES-MS, high performance liquid chromatography/electrospray-mass spectrometry.1Johnston J, ISIS Pharmaceuticals, personal communication. Cited with permission.. Biochemical Pharmacology, 2001, 62, 297-306.	2.0	47
98	RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions. Journal of Clinical Pharmacology, 2017, 57, S43-S59.	1.0	46
99	Progress in antisense therapeutics. , 1996, 16, 319-344.		45
100	Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides. PLoS ONE, 2014, 9, e101752.	1.1	45
101	Dynamic nucleoplasmic and nucleolar localization of mammalian RNase H1 in response to RNAP I transcriptional R-loops. Nucleic Acids Research, 2017, 45, 10672-10692.	6.5	44
102	Human RNase H1 Is Associated with Protein P32 and Is Involved in Mitochondrial Pre-rRNA Processing. PLoS ONE, 2013, 8, e71006.	1.1	43
103	Human Dicer Binds Short Single-strand and Double-strand RNA with High Affinity and Interacts with Different Regions of the Nucleic Acids. Journal of Biological Chemistry, 2009, 284, 2535-2548.	1.6	42
104	Lipid Nanoparticles Improve Activity of Single-Stranded siRNA and Gapmer Antisense Oligonucleotides in Animals. ACS Chemical Biology, 2013, 8, 1402-1406.	1.6	41
105	Application of a tissue culture microtiter test for the detection of cytotoxic agents from natural products.. Journal of Antibiotics, 1985, 38, 758-766.	1.0	40
106	Identification of specific binding sites for leukotriene C4 in human fetal lung. Prostaglandins, 1984, 27, 961-974.	1.2	39
107	Human RNase H1 Uses One Tryptophan and Two Lysines to Position the Enzyme at the 3â€²-DNA/5â€²-RNA Terminus of the Heteroduplex Substrate. Journal of Biological Chemistry, 2003, 278, 49860-49867.	1.6	39
108	Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2013, 1829, 455-468.	0.9	36

#	Article	IF	Citations
109	Binding of a novel dopaminergic agonist radioligand [3H]-fenoldopam1 (SKF 82526) to D-1 receptors in rat striatum. Life Sciences, 1985, 36, 1427-1436.	2.0	35
110	The Positional Influence of the Helical Geometry of the Heteroduplex Substrate on Human RNase H1 Catalysis. Molecular Pharmacology, 2007, 71, 73-82.	1.0	35
111	mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway. Nucleic Acids Research, 2019, 47, 6900-6916.	6.5	32
112	Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes. Nucleic Acids Research, 2020, 48, 1372-1391.	6.5	32
113	Mitotane (o, pâ€²-DDD). Cancer Treatment Reviews, 1980, 7, 49-55.	3.4	31
114	Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 â€˜Slicerâ€™ independent and can be mediated by Ago1. Nucleic Acids Research, 2009, 37, 6927-6941.	6.5	31
115	COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways. Nucleic Acids Research, 2018, 46, 10225-10245.	6.5	31
116	Delivery of Oligonucleotides and Polynucleotides. Journal of Drug Targeting, 1995, 3, 185-190.	2.1	30
117	Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. Journal of Controlled Release, 1996, 41, 121-130.	4.8	30
118	Human RNases H. Methods in Enzymology, 2001, 341, 430-440.	0.4	30
119	Proof of Mechanism of Antisense Drugs. Oligonucleotides, 1996, 6, 145-147.	4.4	28
120	Differential effects of aspirin and dexamethasone on phospolipase A2 and C activities and arachidonic acid release from endothelial cells in respose to bradykinin and leukotriene D4. Prostaglandins, 1986, 32, 703-708.	1.2	27
121	Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1. Nucleic Acids Research, 2019, 47, 10865-10880.	6.5	27
122	Site-specific incorporation of 5â€²-methyl DNA enhances the therapeutic profile of gapmer ASOs. Nucleic Acids Research, 2021, 49, 1828-1839.	6.5	26
123	Depletion of NEAT1 lncRNA attenuates nucleolar stress by releasing sequestered P54nrb and PSF to facilitate c-Myc translation. PLoS ONE, 2017, 12, e0173494.	1.1	26
124	Cellular interactions of auranofin and a related gold complex with raw 264.7 macrophages. Biochemical Pharmacology, 1987, 36, 647-654.	2.0	23
125	Altered expression and transcription of the topoisomerase II gene in nitrogen mustard-resistant human cells. Biochemical Pharmacology, 1988, 37, 4413-4416.	2.0	23
126	Leukotriene C4 ([3H] - LTC4) binding to membranes isolated from a hamster smooth muscle cell line (DDTIMF2). Life Sciences, 1984, 35, 441-448.	2.0	22

#	Article	IF	Citations
127	Identification of leukotriene D4 specific binding sites in the membrane preparation isolated from guinea pig lung. Prostaglandins, 1984, 28, 805-822.	1.2	22
128	Oligonucleotide therapy. Current Opinion in Biotechnology, 1992, 3, 656-661.	3.3	22
129	Antisense Oligonucleotides Targeting Human Protein Kinase C-Î± Inhibit Phorbol Ester-Induced Reduction of Bradykinin-Evoked Calcium Mobilization in A549 Cells. Molecular Pharmacology, 1997, 51, 209-216.	1.0	22
130	A call to arms against ultra-rare diseases. Nature Biotechnology, 2021, 39, 671-677.	9.4	22
131	Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and leukemia group B study #7804. Cancer, 1982, 49, 1346-1352.	2.0	21
132	Effects of coordinated gold compounds on in vitro and in situ DNA replication. Biochemical Pharmacology, 1985, 34, 3243-3250.	2.0	21
133	Inter-strand cross-links and single-strand breaks produced by gold(I) and gold(III) coordination complexes. Biochemical Pharmacology, 1986, 35, 1435-1443.	2.0	21
134	Human RNase H1 Activity Is Regulated by a Unique Redox Switch Formed between Adjacent Cysteines. Journal of Biological Chemistry, 2003, 278, 14906-14912.	1.6	21
135	Cisplatin pharmacokinetics in a patient with renal dysfunction. Medical and Pediatric Oncology, 1978, 5, 183-188.	1.0	20
136	Effect of Antisense Oligonucleotides on Cytokine Release from Human Keratinocytes in anin VitroModel of Skin. Toxicology and Applied Pharmacology, 1996, 140, 85-93.	1.3	20
137	The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. Toxicology and Applied Pharmacology, 1987, 90, 377-390.	1.3	19
138	U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP. Nucleic Acids Research, 2011, 39, e71-e71.	6.5	19
139	Regulation of agonist and antagonist binding to striatal D-1 dopamine receptors: Studies using the selective D-1 antagonist [3H]SK&F R-83566. Life Sciences, 1986, 38, 2087-2096.	2.0	18
140	Desensitization of vasopressin sensitive adenylate cyclase by vasopressin and phorbol esters. Cellular Signalling, 1990, 2, 153-160.	1.7	18
141	Comparison of bleomycin A2 and talisomycin a specific fragmentation of linear duplex DNA. Biochemical and Biophysical Research Communications, 1979, 91, 871-877.	1.0	17
142	Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency. PLoS ONE, 2014, 9, e110615.	1.1	17
143	Induction of functional Î²-adrenergic receptors in rat aortic smooth muscle cells by sodium butyrate. Biochemical Pharmacology, 1986, 35, 3813-3820.	2.0	16
144	Phorbol 12-myristate 13-acetate inhibition of leukotriene D4-induced signal transduction was rapidly reversed by staurosporine. Biochemical and Biophysical Research Communications, 1988, 157, 521-529.	1.0	16

#	Article	IF	Citations
145	The effects of prior exposure to bleomycin on the incidence of pulmonary toxicities in a group of patients with disseminated testicular carcinomas. Medical and Pediatric Oncology, 1978, 5, 93-98.	1.0	15
146	Zinostatin (neocarzinostatin). Cancer Treatment Reviews, 1979, 6, 239-249.	3.4	15
147	Evaluating the Mechanism of Action of Antiproliferative Antisense Drugs. Oligonucleotides, 2000, 10, 123-126.	4.4	15
148	Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs. Nucleic Acids Research, 2018, 46, 293-313.	6.5	15
149	Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides. Molecular Therapy - Nucleic Acids, 2018, 13, 686-698.	2.3	15
150	Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity. Nucleic Acids Research, 2020, 48, 9840-9858.	6.5	14
151	The transition metal binding properties of a 3RD generation bleomycin analogue, tallysomycin. Biochemical and Biophysical Research Communications, 1978, 85, 1407-1414.	1.0	13
152	Variations in mRNA Content Have No Effect on the Potency of Antisense Oligonucleotides. Oligonucleotides, 2000, 10, 453-461.	4.4	13
153	Site-specific Incorporation of 2â€²,5â€²-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides. ACS Medicinal Chemistry Letters, 2021, 12, 922-927.	1.3	13
154	Interaction of covalently closed circular PM-2 DNA and hedamycin. Biochemical and Biophysical Research Communications, 1979, 88, 237-243.	1.0	11
155	Structure-activity relationships involved in the site-specific fragmentation of linear duplex DNAs by talisomycin and bleomycin analogs. Cancer Chemotherapy and Pharmacology, 1982, 8, 57-65.	1.1	11
156	Antisense technology. Current Opinion in Biotechnology, 1991, 2, 282-287.	3.3	11
157	Progress in Evaluation of the Potential of Antisense Technology. Antisense Research and Development, 1994, 4, 145-146.	3.3	11
158	Mechanisms of Antisense Drug Action, an Introduction. , 2007, , 3-46.		11
159	Identification of the active species in deoxyribonucleic acid breakage induced by 4â€²-(9-acridinylamino)methanesulfon-m-anisidide and copper. Biochemical Pharmacology, 1986, 35, 1071-1078.	2.0	10
160	Selective purification of cardiac myosin by a high-performance salicylate affinity column. Journal of Chromatography A, 1988, 435, 185-192.	1.8	10
161	Chromosomal mapping of the ubiquitin gene family inSaccharomyces cerevisiaeby pulsed field gel electrophoresis. Nucleic Acids Research, 1989, 17, 3611-3612.	6.5	10
162	siRNAs targeted to certain polyadenylation sites promote specific, RISC-independent degradation of messenger RNAs. Nucleic Acids Research, 2012, 40, 6223-6234.	6.5	10

#	Article	IF	Citations
163	RNA helicase A is not required for RISC activity. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2013, 1829, 1092-1101.	0.9	10
164	Interaction of ASOs with PC4 Is Highly Influenced by the Cellular Environment and ASO Chemistry. Journal of the American Chemical Society, 2020, 142, 9661-9674.	6.6	10
165	Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins. Nucleic Acids Research, 2021, 49, 2721-2739.	6.5	10
166	Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective. Nucleic Acid Therapeutics, 2021, 31, 126-144.	2.0	10
167	Addressing the Needs of Patients with Ultra-Rare Mutations One Patient at a Time: The n-Lorem Approach. Nucleic Acid Therapeutics, 2022, 32, 95-100.	2.0	10
168	Comparison of two radioimmunoassays and a microbiologic assay for bleomycin. Medical and Pediatric Oncology, 1978, 5, 213-218.	1.0	9
169	Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: An analysis. Medical and Pediatric Oncology, 1979, 6, 195-205.	1.0	9
170	Evidence for tyrosine at the ligand binding center of beta-adrenergic receptors. Biochemical Pharmacology, 1986, 35, 3821-3825.	2.0	9
171	Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly. Nucleic Acid Therapeutics, 2019, 29, 343-358.	2.0	9
172	Pediatric cancer chemotherapy: an updated review. Cancer Treatment Reviews, 1979, 6, 153-164.	3.4	8
173	HPLC Analysis of [³H]-Arachidonic Acid Metabolites Produced by Smooth Muscle and Endothelial Cells in Response to Leukotriene D₄. Journal of Liquid Chromatography and Related Technologies, 1987, 10, 2707-2719.	0.9	8
174	Homologous and heterologous desensitization mediated by vasopressin in smooth muscle cells. Cellular Signalling, 1989, 1, 241-251.	1.7	8
175	Oligonucleotide Therapeutics: A Prospectus. Antisense Research and Development, 1993, 3, 1-2.	3.3	8
176	Meeting the needs of patients with ultrarare diseases. Trends in Molecular Medicine, 2022, 28, 87-96.	3.5	8
177	Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms. Nucleic Acid Therapeutics, 2020, 30, 312-324.	2.0	7
178	Golgi-58K can re-localize to late endosomes upon cellular uptake of PS-ASOs and facilitates endosomal release of ASOs. Nucleic Acids Research, 2021, 49, 8277-8293.	6.5	7
179	RNA modifications can affect RNase H1-mediated PS-ASO activity. Molecular Therapy - Nucleic Acids, 2022, 28, 814-828.	2.3	7
180	Effects of several anthracycline antitumor antibiotics on the transcriptional activity of isolated nucleoli.. Journal of Antibiotics, 1980, 33, 1048-1053.	1.0	6

#	Article	IF	Citations
181	Phase II evaluation of mitomycin C (MMC) in children with refractory solid tumors using the single high-intermittent-dose schedule. Medical and Pediatric Oncology, 1981, 9, 405-407.	1.0	6
182	Formation of the thiol adducts of 4â€²-(9-acridinylamino)methanesulfon-m-anisidide and their binding to deoxyribonucleic acid. Biochemical Pharmacology, 1986, 35, 1655-1662.	2.0	6
183	Vasopressin V1 receptors and inter-receptor regulation in vascular smooth muscle cells. Biochemical Pharmacology, 1988, 37, 2105-2108.	2.0	6
184	The concept and application of antisense oligonucleotides. Diseases of the Colon and Rectum, 2001, 44, 1241-1243.	0.7	6
185	The13C NMR spectra of tallysomycin and its zinc(II) complex. Magnetic Resonance in Chemistry, 1980, 13, 270-273.	0.7	5
186	Section Review Biologicals & Immunologicals: Progress in the development and patenting of antisense drug discovery technology. Expert Opinion on Therapeutic Patents, 1996, 6, 855-870.	2.4	5
187	DNA breakage activity of the methanol extract of auromomycin. Cancer Chemotherapy and Pharmacology, 1981, 7, 41-50.	1.1	4
188	Comparison of the response of synchronized Hela cells to talisomycin and bleomycin. Cancer Chemotherapy and Pharmacology, 1981, 5, 251-256.	1.1	4
189	A vector for construction of gene libraries and the expression of heterologous genes in Saccharomyces cerevisiae. Plasmid, 1987, 17, 171-172.	0.4	4
190	Possible involvement of protein kinase C and cyclic AMP-dependent protein kinase in the sodium fluoride-mediated inhibition of cyclic nucleotide accumulation in smooth muscle cells. Cellular Signalling, 1990, 2, 531-536.	1.7	4
191	The Future of Sequence-Specific Transcriptional Inhibition. Cancer Investigation, 1996, 14, 89-90.	0.6	4
192	New drugs and changing disease paradigms. Nature Biotechnology, 1996, 14, 238-241.	9.4	4
193	Comments on Evaluation of Antisense Drugs in the Clinic. Oligonucleotides, 2000, 10, 225-227.	4.4	4
194	Hsc70 Facilitates Mannose-6-Phosphate Receptor-Mediated Intracellular Trafficking and Enhances Endosomal Release of Phosphorothioate-Modified Antisense Oligonucleotides. Nucleic Acid Therapeutics, 2021, 31, 284-297.	2.0	4
195	Pharmacokinetics of carminomycin in dogs and humans. Cancer Chemotherapy and Pharmacology, 1981, 6, 189-93.	1.1	3
196	Studies on the fluorescence labeling of human red blood cell membrane ghosts with 4â€²-(9-acridinylamino) methanesulfon-m-anisidide. Biochemical Pharmacology, 1985, 34, 3265-3273.	2.0	3
197	[51] Purification of guinea pig uterus phosphoinositide-specific phospholipase C. Methods in Enzymology, 1991, 197, 526-535.	0.4	3
198	RNA directed therapeutics: mechanisms and status. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e109-e117.	0.5	3

#	Article	IF	Citations
199	Perinuclear positioning of endosomes can affect PS-ASO activities. Nucleic Acids Research, 2021, 49, 12970-12985.	6.5	3
200	Effects of cis-diamminedichloroplatinum (CDDP) on HeLa cell non-histone nuclear proteins. Cancer Chemotherapy and Pharmacology, 1982, 9, 36-40.	1.1	2
201	Altered actin and immunoglobulin C? expression in nitrogen mustard-resistant human Burkitt lymphoma cells. Journal of Cellular Biochemistry, 1989, 40, 407-415.	1.2	2
202	Preparation and Use of ZFY-6 Zinc Finger Ribonuclease. Methods in Enzymology, 2001, 341, 490-500.	0.4	2
203	The RNase H Mechanism. , 2007, , 47-74.		2
204	Monthly Updates: Monthly Update Biologicals & Immunologicals: Progress in the development of antisense drugs. Expert Opinion on Investigational Drugs, 1996, 5, 1047-1052.	1.9	2
205	Health Security Preparedness and Industry Trends. Health Security, 2015, 13, 74-81.	0.9	1
206	Progress in molecular biology and translational science addressing the needs of nano-rare patients. Progress in Molecular Biology and Translational Science, 2022, , 127-146.	0.9	1
207	Leukotriene Receptors and Mechanisms of Signal Transduction. Annals of the New York Academy of Sciences, 1991, 629, 120-124.	1.8	0
208	Genotypic drug discovery: what does the future hold?. Trends in Biotechnology, 1999, 17, 10-11.	4.9	0
209	Renovation of the new medicine regulatory process. Clinical Research and Regulatory Affairs, 2011, 28, 81-86.	2.1	0
210	Solubilization of Vasopressin Receptors. Methods in Neurosciences, 1991, 5, 185-192.	0.5	0
211	Establishing an environment in which rigorous scientific inquiry is practiced: a personal journey. Nucleic Acids Research, 2022, 50, 7216-7223.	6.5	0